Pharmacokinetics and drug interactions: Update for new antipsychotics

Journal of Clinical Psychiatry

Volumn 57, Issue SUPPL. 11, 1996, Pages 12-25

  Ereshefsky, Larry ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 NITROPHENOL; ASTEMIZOLE; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CHLORAMPHENICOL; CHLORPROMAZINE; CIMETIDINE; CLOZAPINE; DIAZEPAM; ERYTHROMYCIN; FLUOXETINE; FLUPENTIXOL; FLUPHENAZINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; FURAFYLLINE; HALOPERIDOL; ITRACONAZOLE; KETOCONAZOLE; NEUROLEPTIC AGENT; OLANZAPINE; PANTOFENICOL; PERPHENAZINE; PHENYTOIN; QUETIAPINE; QUINIDINE; QUINIDINE GLUCONATE; RISPERIDONE; SERTINDOLE; THIORIDAZINE; TIOTIXENE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIPRASIDONE;

DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG SCREENING; HUMAN; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; HALF-LIFE; HUMANS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0029969184     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Ereshefsky L. Treatment strategies for schizophrenia. Psychiatric Annals 1995;25:285-296
2. Ereshefsky L, Tran-Johnson T, Watanabe MD. Current concepts in the treatment of schizophrenia: the pathophysiologic basis for atypical antipsychotic efficacy. Clin Pharm 1990;8:680-707
3. Goldstein JM. Pre-clinical pharmacology of new atypical antipsychotics in late stage development. Exp Opinion Invest Drugs 1995;4:291-298
4. Kinon BJ, Lieberman JA. Mechanism of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology (Berl) 1996;124:2-34
5. Ereshefsky L, Richards A. Psychosis. In: Koda-Kimble MA, Young LL, eds. Applied Therapeutics: The Clinical Use of Drugs. San Francisco, Calif: Applied Therapeutics Press; 1992
6. Ereshefsky L, Jann MW, Saklad SR, et al. Bioavailability of psychotropic drugs: historical perspective and pharmacokinetic overview. J Clin Psychiatry 1986;47:6-15
7. Ereshefsky L, Saklad SR, Jann MW, et al. Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches. J Clin Psychiatry 1984;45(5, sec 2):50-59
8. Ereshefsky L, Saklad SR, Davis CM, et al. Pharmacokinetics of fluphenazine by high performance thin layer chromatography [abstract]. Drug Intelligence and Clinical Pharmacy 1983;17:436
9. Saklis G, Curry SH, Mould GP, et al. Physiologic and clinical effects of chlorpromazine and their relationship to plasma level. Clin Pharmacol Ther 1972;13:931-946
10. Ereshefsky L, Saklad SR, Watanabe MD, et al. Thiothixene pharmacokinetic interactions: a study of hepatic enzyme inducers, clearance inhibitors, and demographic variables. J Clin Psychopharmacol 1991;11:296-301
11. Balant-Gorgia AE, Balant L. Antipsychotic drugs: clinical pharmacokinetics of potential candidates for plasma concentration monitoring. Clin Pharmacokinet 1987;13:65-90
12. Wong YWJ, Ewing BJ, Fabre LF, et al. Multiple-dose pharmacokinetics of quetiapine in male schizophrenic patients. Presented at the Collegium Internationale Neuro-Psychopharmacologicum; June 1996; Melbourne, Australia
13. Eli Lilly and Co. New drug application no. 20-592. 1996;96:1-347
14. Lundbeck Limited. Summary of product characteristics, Serdolect®. United Kingdom; 1996
15. Muirhead GJ, Holt GJ, Harness OS, et al. The effect of ziprasidone on steady-state pharmacokinetics of combined oral contraceptives. Presented at Collegium Internationale Neuro-Psychopharmacologicum; June 1996; Melbourne, Australia
16. Choc MG, Hsuan F, Honigfeld G, et al. Single vs multiple dose pharmacokinetics of clozapine in psychiatric patients. Pharm Res 1990;7:347-351
17. Ereshefsky L, Lacombe S. Pharmacological profile of risperidone. Can J Psychiatry 1993;38(3, suppl):S80-S88
18. DeVane CL. Drug interactions and antipsychotic therapy. Pharmacotherapy 1996;16(suppl):15S-20S
19. Ward ME, Saklad SR, Ereshefsky L. Lorazepam in treatment of psychotic agitation [letter]. Am J Psychiatry 1986;143:1195
20. Arana GW, Ornsteen ML, Kauter F, et al. The use of benzodiazepines for psychotic disorders: a literature review and preliminary clinical findings. Psychopharmacol Bull 1986;22:77-99
21. Verghese C, Kessel JB, Simpson G. Pharmacokinetics of neuroleptics. Psychopharmacol Bull 1991;27:551-563
22. Ereshefsky L, LeRoy A, Tran-Johnson T, et al. Pharmacokinetic factors affecting antidepressant drug clearance and clinical effect: evaluation of doxepin and imipramine: new data and review. Clin Chem 1988;34: 863-880
23. Wilner KD, Hansen RA, Johnson AC, et al. Single and multiple dose pharmacokinetics of ziprasidone in healthy males. Presented at the Collegium Internationale Neuro-Psychopharmacologicum; June 1996; Melbourne, Australia
24. Gibaldi M, Perrier D. Pharmacokinetics. In: Drugs and the Pharmaceutical Sciences, vol 15. New York, NY: Marcel Dekker; 1982:1-60
25. Ereshefsky L, Saklad SR, Tran-Johnson T, et al. Kinetics and clinical evaluation of haloperidol decanoate loading dose regimen. Psychopharmacol Bull 1990;26:108-114
26. Ereshefsky L, Saklad SR, Davis CM, et al. Clinical implications of fluphenazine kinetics. Presented at the American Psychiatric Association; 1984; New York, NY
27. Hasegawa M, Gutierrez-Estinou R, Way L, et al. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. J Clin Psychopharmacol 1993;13:383-390
28. Ereshefsky LE, Riesenman C, Lam YWF. Antidepressant drug interactions and the cytochrome P450 system: the role of CYP2D6. Clin Pharmacokinet 1995;29(suppl):10-19
29. Ereshefsky L, Riesenman C, Lam YWF. Serotonin selective reuptake inhibitor drug interactions and the cytochrome P450 system. J Clin Psychiatry 1996;57(8, suppl):17-25
30. Ereshefsky L. Drug-drug interactions involving antidepressants: focus on venlafaxine. J Clin Psychopharmacol 1996;16(suppl):37-53
31. Ring BJ, Catlow J, Lindsay TJ, et al. Identification of the human cytochrome P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther 1996;276:658-666
32. Ring BJ, Binkley SN, Vandenbranden M, et al. In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6, and CYP3A. Br J Clin Pharmacol 1996;41:181-186
33. Jann MW, Chang W-H, Davis CM, et al. Haloperidol and reduced haloperidol plasma levels in Chinese vs non-Chinese psychiatric patients. Psychiatry Res 1989;30:45-32
34. Chang W-H, Jann MW, Hwu H-G, et al. Ethnic comparison of haloperidol and reduced haloperidol plasma levels: Taiwan Chinese versus American non-Chinese. J Formos Med Assoc 1991;90:572-578
35. Jann MW, Grimsely S, Gray E, et al. Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet 1993;24:161-176
36. Haring C, Meise U, Humpel A, et al. Dose-related plasma levels of clozapine: influence of smoking behavior, sex, and age. Psychopharmacology (Berl) 1989;99(suppl):38-40
37. Anderson CB, True JE, Ereshefsky L, et al. Risperidone clinical efficacy: role of the metabolite 9-hydroxy-risperidone. In: Abstract of the New Clinical Drug Evaluation Unit Annual Meeting; June 1993; Boca Raton, Fla
38. Ereshefsky L, Anderson CB, True J, et al. Plasma concentration of oral risperidone and active metabolite in schizophrenics. In: Abstract of the American College of Clinical Pharmacy Meeting; August 1993; Reno, Nev
39. Huang ML, Van Peer A, Woestenborghs R, et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 1993;54:257-268
40. Shin SG, Chong WS, Jang IJ, et al. Association of risperidone metabolism with debrisoquine hydroxylation [abstract]. Presented at the 5th World Conference on Clinical Pharmacology and Therapeutics; July 1992; Yokohama, Japan
41. Anderson CB, True JE, Ereshefsky L, et al. Risperidone dose, plasma levels and response. Presented at the 146th Annual Meeting of the American Psychiatric Association; May 1993; San Francisco, Calif
42. Fulton B, Goa KL. ICI-204,636: an initial appraisal of its pharmacological properties and clinical potential in the treatment of schizophrenia. CNS Drugs 1995;4:68-78
43. Shimada E, Muraski M, Miura S, et al. A phase I study in healthy volunteers of ICI204636, a novel neuroleptic agent [abstract]. Int J Physiol Pharmacol 1994;445(suppl 1)
44. Fabre LF, Aravanitis L, Pultz J, et al. ICI 204,636 a novel atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia. Clin Ther 1995;17:366-378
45. Hollister LE. Antipsychotic drugs. In: Hollister LE, ed. Clinical use of psychotherapeutic drugs. Springfield, Ill: Charles C. Thomas; 1973:13-55
46. Ereshefsky L, Davis CM, Harrington CA, et al. Haloperidol and reduced haloperidol plasma levels in selected schizophrenic patients. J Clin Psychopharmacol 1984;4:138-142
47. Ereshefsky L, Watanabe MD, Tran-Johnson T. Clozapine: an atypical antipsychotic. Clin Pharm 1989;8:691-709
48. Jann MW, Ereshefsky L, Saklad SR, et al. Effects of carbamazepine on plasma haloperidol levels. J Clin Psychopharmacol 1985;5:106-109
49. Kidron R, Averbuch I, Klein E, et al. Carbamazepine induction reduction of blood levels of haloperidol in chronic schizophrenia. Biol Psychiatry 1985;20:219-222
50. Linnoila M, Viukari M, Vaisanen K, et al. Effect of anticonvulsants on plasma haloperidol and thioridazine levels. Am J Psychiatry 1980;137: 819-821
51. Miller D. Effects of phenytoin on plasma clozapine concentrations in two patients. J Clin Psychiatry 1991;52:23-25
52. Jerling M, Lindstrom L, Bondesson U, et al. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine. Ther Drug Monit 1994;6:368-374
53. Funderburg LG, Vertrees JE, True JE, et al. Seizure after the addition of erythromycin to clozapine treatment. Am J Psychiatry 1994;151: 1840-1841
54. Riskin TS. Effect of clozapine on plasma nortriptyline concentration. Pharmacopsychiatry 1994;27:41-42
55. Jann MW, Saklad SR, Ereshefsky L, et al. Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance. Psychopharmacology (Berl) 1986;90:468-470
56. Ereshefsky L, Jann MW, Saklad SR, et al. Effects of smoking on fluphenazine clearance in psychiatric inpatients. Biol Psychiatry 1985;20:329-352
57. Stimmel GL, Falloon IRH. Chlorpromazine plasma levels, adverse effects, and tobacco smoking: case report. J Clin Psychiatry 1983;44:420-422
58. Santos JL, Calabranes JA, Almoquera I, et al. Clinical implications of determination of plasma haloperidol levels. Acta Psychiatr Scand 1989; 79:348-354
59. Smith RC, Baumgarten R, Misra CH, et al. Haloperidol plasma levels and prolactin response as predictors of clinical improvement in schizophrenia. Arch Gen Psychiatry 1984;41:1044-1049
60. Mavroidis ML, Kanter DR, Hirschowitz J. Clinical response and plasma levels in schizophrenia. Psychopharmacology (Berl) 1983;81:354-356
61. Potkin SG, Shen Y, Zhou D, et al. Does a therapeutic window for plasma haloperidol exist? Psychopharmacol Bull 1985;21:59-61
62. Volovka J, Cooper TB, Meisner M, et al. Haloperidol blood levels and effects in schizophrenia and schizoaffective disorders. Psychopharmacol Bull 1990;26:13-17
63. Van Putten T, Marder SR, Wirshing WC, et al. Neuroleptic plasma levels. Schizophr Bull 1991;17:197-216
64. Dysken MW, Javaid JI, Chang SS, et al. Fluphenazine pharmacokinetics and therapeutic response. Psychopharmacology (Berl) 1981;73:205-210
65. Mavroidis ML, Kanter DR, Hirschowitz J. Fluphenazine plasma levels and clinical response. J Clin Psychiatry 1984;45:370-373
66. Levinson DF, Simpson GM, Singh H, et al. Neuroleptic plasma level may predict response in patients who meet a criterion for improvement [letter]. Arch Gen Psychiatry 1988;45:877-879
67. Perry PJ, Miller DD, Arndt SV. Clozapine and norclozapine concentrations and clinical response of treatment refractory patients. Am J Psychiatry 1991;148:231-235
68. Jann MW, Ereshefsky L, Saklad SR, et al. Haloperidol and reduced haloperidol plasma levels in schizophrenic patients. Drug Intel Clin Pharm 1984;18:507